Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer

Strahlentherapie und Onkologie

Volumn 190, Issue 7, 2014, Pages 636-645

  Lazaridis, Georgios ^a   Lambaki, Sofia ^a   Karayannopoulou, Georgia ^a   Eleftheraki, Anastasia G ^b   Papaspirou, Irene ^c   Bobos, Mattheos ^a   Efstratiou, Ioannis ^d   Pentheroudakis, George ^e   Zamboglou, Nikolaos ^f   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f Klinikum Offenbach   (Germany)

Author keywords

Breast cancer; p Akt; p mTOR; Predictive value; Prognostic value

Indexed keywords

EPIRUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR;

ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GREECE; HUMANS; INCIDENCE; ONCOGENE PROTEIN V-AKT; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84903385160     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0620-6     Document Type: Article

References (31)

1. Lassere MN, Johnson KR, Boers M et al (2007) Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J rheumatol 34:607-615 (Pubitemid 46364019)
2. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
3. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
4. Gomez-Pinillos A, Ferrari AC (2012) mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 26:483-505, vii
5. Cordes N, Rodel F, Rodemann HP (2012) Molecular signaling pathways. Mechanisms and clinical use. Strahlenther Onkol 188(Suppl 3):308-311
6. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. N Engl J Med 366:520-529
7. Schroeder W, Biesterfeld S, Zillessen S, Rath W (1997) Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17:2799-2802 (Pubitemid 27352690)
8. Fujita T, Doihara H, Kawasaki K et al (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:247-252 (Pubitemid 43151543)
9. Razis E, Bobos M, Kotoula V et al (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128:447-456
10. Tokunaga E, Kataoka A, Kimura Y et al (2006) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42:629-635 (Pubitemid 43343685)
11. Fountzilas G, Skarlos D, Dafni U et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762-1771 (Pubitemid 41631238)
12. Fountzilas G, Dafni U, Gogas H et al (2008) Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 19:853-860 (Pubitemid 351649185)
13. Gogas H, Dafni U, Karina M et al (2012) Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat 132:609-619
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235 (Pubitemid 44631925)
15. Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127-2132 (Pubitemid 46972801)
16. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10:51
17. Ueng SH, Chen SC, Chang YS et al (2012) Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clinical Exp Pathol 5:806-813
18. Garcia Castro C, Ravina M, Castro V, Salido EC (1993) Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet 252:169-177 (Pubitemid 23131623)
19. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S (1993) Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma. J Clin Pathol 46:1009-1010
20. Newby JC, A'Hern RP, Leek RD, Smith IE, Harris AL, Dowsett M (1995) Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br J Cancer 71:1237-1242
21. Ferrero JM, Ramaioli A, Largillier R et al (2001) Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12:841-846 (Pubitemid 32655096)
22. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71:67-75 (Pubitemid 34121818)
23. Dittmann K, Mayer C, Rodemann HP (2010) Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol 186:1-6
24. Bose S, Chandran S, Mirocha JM, Bose N (2006) The Akt pathway in human breast cancer: a tissue-array- based analysis. Mod Pathol 19:238-245 (Pubitemid 43117608)
25. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204:93-100 (Pubitemid 39214486)
26. Zhou X, Tan M, Stone Hawthorne V et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 over-expression predicts tumor progression in breast cancers. Clin Cancer Res 10:6779-6788 (Pubitemid 39383026)
27. Perez-Tenorio G, Alkhori L, Olsson B et al (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577-3584 (Pubitemid 46955118)
28. Sedlmayer F, Sautter-Bihl ML, Budach W et al (2013) DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 189:825-833
29. Souchon R, Sautter-Bihl ML, Sedlmayer F et al (2014) DEGRO practical guidelines: radiotherapy of breast cancer II: Radiotherapy of non-invasive neoplasia of the breast. Strahlenther Onkol 190:8-16
30. Dionysopoulos D, Pavlakis K, Kotoula V et al (2013) Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlenther Onkol 189:202-214
31. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A (2010) Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7:309-317